Pattern of prolactin secretion after administration of gonadotropinreleasing hormone agonist at the preovulatory phase of intrauterine insemination cycles

CONTEXT AND OBJECTIVE: Administration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for trigger- ing ovulation in assisted reproductive technology cycles. The aim of this work was to investigate the pattern of prolactin secretion after the admin- istration...

Descripción completa

Detalles Bibliográficos
Autores: Cavagna, Mario, Mantese, João Carlos, Freitas, Gilberto da Costa, Dzik, Artur, Soares, Jonathas Borges, Hameiry, Yaron, Izzo, Vicente Mario, Pinotti, José Aristodemo
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2005
País:Brasil
Institución:Associação Paulista de Medicina
Repositorio:São Paulo medical journal (Online)
Idioma:inglés
OAI Identifier:oai:ojs.diagnosticoetratamento.emnuvens.com.br:article/2369
Acceso en línea:https://periodicosapm.emnuvens.com.br/spmj/article/view/2369
Access Level:acceso abierto
Palabra clave:Gonadorrelina
Indução da ovulação
Infertilidade
Inseminação artificial
Prolactina
Gonadorelin
Ovulation induction
Infertility
Insemination artificial
Prolactin
Descripción
Sumario:CONTEXT AND OBJECTIVE: Administration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for trigger- ing ovulation in assisted reproductive technology cycles. The aim of this work was to investigate the pattern of prolactin secretion after the admin- istration of a single dose of GnRH-agonist at the preovulatory phase. DESIGN AND SETTING: Descriptive study at a tertiary referral center. PARTICIPANTS: Fifteen normally ovulating patients undergoing ovarian stimulation for intrauterine insemination were studied. METHODS: Ovarian stimulation was carried out using human menopausal gonadotropin (intra- muscular 75 IU daily). When at least one follicle reached 17 mm (observed echographically), 0.5 mg of buserelin acetate was administered. Blood samples were taken to determine prolactin concentrations, at the time of agonist injection and 4, 8, 12, 24 and 48 hours later. RESULTS: A statistically significant increase in serum levels of prolactin was observed 4, 8 and 12 hours after GnRH-agonist administration, with a peak at 8 hours. CONCLUSION: The administration of a single dose of GnRH-agonist at the preovulatory phase in patients undergoing ovarian stimulation performed with human menopausal gonadotropin causes a significant increase in serum prolactin levels.